Venture Capital Funding Survey, Fourth Quarter 2014
VENTURE CAPITAL FUNDING, FOURTH QUARTER 2014 This is a listing of many of the Bay Area firms that received venture capital financing between Oct. 1 and Dec. 30, 2014. Most of the data was compiled from a survey conducted by PricewaterhouseCoopers, Thomson Venture Economics and the National Venture Capital Association in conjunction with the Mercury News. In the case of some investments there may have been other participants in the round who are not credited. Also, the amounts listed may not include all venture funding the company received during the quarter. *Indicates this is a seed or first-round infusion of money from venture capitalists. These companies may have received money previously from other investors and aren't necessarily startups.
BIOTECHNOLOGY / HEALTH Name
3-V Biosciences
Aduro BioTech
City
Menlo Park
Berkeley
Stage
Amount
Investors
Description
Later Stage
Therapeutics that Kleiner Perkins Caufield & Byers, modulate pathways for New Enterprise Associates, the treatment of $28,500,000 undisclosed firm oncology
Later Stage
Foresite Capital Management, Morningside Group, OrbiMed $51,388,000 Advisors, undisclosed firms
Clinical research services Clinical-stage biopharmaceutical company
Medical devices
Afferent Pharmaceuticals
San Mateo
Early Stage
Domain Associates, undisclosed $25,103,000 firm
Altura Medical
Menlo Park
Expansion
Advanced Technology Ventures, $10,281,000 undisclosed firm
Early Stage
Treatment of neurodegenerative Clarus Ventures, Novartis Venture and autoimmune $33,999,900 Funds, undisclosed firm disorders
Biotechnology company
Annexon Bioscience*
Redwood City
Audentes Therapeutics
San Francisco
Early Stage
5AM Venture Management, Deerfield Management, OrbiMed Advisors, Sofinnova Ventures, $42,500,200 Venrock, Versant Ventures,
C2 Therapeutics
Redwood City
Expansion
$11,628,000 Undisclosed firm
Medical products and devices
Early Stage
$11,228,000 Undisclosed firm
Genomics hardware/systems for laser printing DNA
Later Stage
Cardiovascular Alberta Investment Management, genomic diagnostics $14,017,000 undisclosed firm company
Cambrian Genomics
CardioDx
San Francisco
Redwood City
Page 1 of 25